Aclaris Therapeutics, Inc. 10-Q

Item 5. Other Information ​ Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements. ​ On August 17, 2023 , Maxine Gowen , a member of our Board of Directors , adopted a Rule 10b5-1 trading plan intended to satisfy the affirmative defense conditions of Rule10b5-1(c)(1) under the Exchange Act. Sales may commence under the plan on November 16, 2023 and the plan terminates on December 31, 2024 , subject to earlier termination in accordance with its terms. The aggregate number of securities to be sold under the plan is 44,801 shares of common stock. ​ Item 6. Exhibits ​ ​ Exhibit No. Document ​ ​ ​ 3.1 ​ Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on October 13, 2015). ​ ​ ​ 3.2 ​ Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-37581), filed with the SEC on August 7, 2023). ​ ​ ​ 3.3 ​ Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37581), filed with the SEC on June 24, 2020). ​ ​ ​ 31.1* ​ Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act. ​ ​ ​ 31.2* ​ Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act. ​ ​ ​ 32.1** ​ Certifications of Principal Executive Officer and Principal Financial Officer under Section 906 of the Sarbanes-Oxley Act. ​ ​ ​ 101.INS ​ XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) 37 Table of Contents ​ ​ ​ 101.SCH ​ Inline XBRL Taxonomy Extension Schema Document ​ ​ ​ 101.CAL ​ Inline XBRL Taxonomy Extension Calculation Linkbase Document ​ ​ ​ 101.DEF ​ Inline XBRL Taxonomy Extension Definition Linkbase Document ​ ​ ​ 101.LAB ​ Inline XBRL Taxonomy Extension Label Linkbase Document ​ ​ ​ 101.PRE ​ Inline XBRL Taxonomy Extension Presentation Linkbase Document ​ ​ ​ 104 ​ Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) ​ * Filed herewith. ** These certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing. ​ 38 Table of Contents SIGNATURES ​ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ ​ ​ ​ ​ ACLARIS THERAPEUTICS, INC. ​ ​ ​ Date: November 6, 2023 By: /s/ Douglas Manion ​ ​ Douglas Manion ​ ​ President and Chief Executive Officer ​ ​ (On behalf of the Registrant) ​ ​ ​ ​ ​ ​ Date: November 6, 2023 By: /s/ Kevin Balthaser ​ ​ Kevin Balthaser ​ ​ Chief Financial Officer ​ ​ (Principal Financial Officer) ​ ​ ​ 39